tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALDX Stock Latest News

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics
RatingsPromising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics
8d ago
ALDX
Aldeyra price target raised to $7 from $6 at Jefferies
PremiumThe Fly
Aldeyra price target raised to $7 from $6 at Jefferies
8d ago
ABBV
ALDX
Aldeyra receives orphan designation from EMA for ADX-2191
PremiumThe Fly
Aldeyra receives orphan designation from EMA for ADX-2191
2M ago
ALDX
Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
PremiumCompany Announcements
Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
2M ago
8K
ALDX
Aldeyra granted fast track designation for ADX-2191 by FDA
PremiumThe Fly
Aldeyra granted fast track designation for ADX-2191 by FDA
2M ago
ALDX
Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
PremiumRatingsAldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
2M ago
ALDX
Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
Premium
Ratings
Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
2M ago
ALDX
Aldeyra receives orphan designation for ADX-2191 from EMA
Premium
The Fly
Aldeyra receives orphan designation for ADX-2191 from EMA
3M ago
ALDX
FDA Accepts Aldeyra’s Reproxalap Application for Review
PremiumCompany Announcements
FDA Accepts Aldeyra’s Reproxalap Application for Review
3M ago
8K
ALDX
Aldeyra announces FDA acceptance for review of reproxalap NDA
PremiumThe Fly
Aldeyra announces FDA acceptance for review of reproxalap NDA
3M ago
ALDX
Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
PremiumRatings
Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
4M ago
ALDX
Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
PremiumCompany Announcements
Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
4M ago
8K
ALDX
Aldeyra receives special protocol assessment agreement letter from FDA
PremiumThe FlyAldeyra receives special protocol assessment agreement letter from FDA
4M ago
ALDX
Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
4M ago
ALDX
Aldeyra Resubmits Reproxalap NDA to FDA
Premium
Company Announcements
Aldeyra Resubmits Reproxalap NDA to FDA
4M ago
8K
ALDX
Aldeyra resubmits topical ocular reproxalap NDA to FDA
PremiumThe Fly
Aldeyra resubmits topical ocular reproxalap NDA to FDA
4M ago
ALDX
Aldeyra Therapeutics Holds Annual Meeting with Key Votes
PremiumCompany Announcements
Aldeyra Therapeutics Holds Annual Meeting with Key Votes
4M ago
8K
ALDX
Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating
PremiumRatings
Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating
5M ago
ALDX
Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships
PremiumRatings
Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships
5M ago
ALDX
Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
PremiumRatingsAldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
5M ago
ALDX
Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
Premium
Ratings
Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
5M ago
ALDX
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
Premium
Company Announcements
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
5M ago
8K
ALDX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >